Company Encyclopedia
View More
name
Agenus
AGEN.US
Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies.
1.946 T
AGEN.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking264/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE12.49%B
    • Profit Margin-32.92%E
    • Gross Margin19.83%D
  • Growth ScoreD
    • Revenue YoY-33.41%E
    • Net Profit YoY84.47%A
    • Total Assets YoY-1.93%D
    • Net Assets YoY-3.33%D
  • Cash ScoreE
    • Cash Flow Margin-301.93%D
    • OCF YoY-33.41%E
  • Operating ScoreC
    • Turnover0.45C
  • Debt ScoreE
    • Gearing Ratio220.08%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Agenus Inc. Hosts Stakeholder Webcast Showcasing BOT/BAL Progress and GI Oncology Advances

    Agenus Inc. will host its End-of-Year 2025 Stakeholder Webcast on December 3, 2025, at 4:00 p.m. ET. The event will update on the BOT/BAL program, clinical insights in gastrointestinal oncology, and the Phase 3 BATTMAN study. Experts and patient advocates will participate, concluding with a live Q&A. This AI-generated news is for informational purposes only.

    Reuters·
    US
    AGEN
    -2.64%
    Reuters·
    US
    AGEN
    -2.64%

    Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer

    Agenus Inc. has appointed Dr. José Iglesias as Chief Medical Affairs Officer, effective November 10, 2025. He will lead global medical affairs for the company's immuno-oncology programs, focusing on botensilimab and balstilimab for colorectal cancer.

    Reuters·
    US
    AGEN
    -2.64%
    Reuters·
    US
    AGEN
    -2.64%

    Agenus Inc. Reports Q3 2025 Financial and Clinical Progress

    Agenus Inc. (AGEN) reported its Q3 2025 earnings, highlighting significant clinical advancements, including the initiation of a global Phase 3 trial for its BOT/BAL therapy in refractory colorectal cancer. The company achieved a net income due to the deconsolidation of MiNK and secured a $10 million bridge facility from Zydus. Promising survival rates were noted for BOT/BAL in advanced solid tumors. Agenus is focused on expanding patient access and advancing its clinical programs, with key milestones expected in the coming months.

    Tip Ranks·
    US
    AGEN
    -2.64%
    Tip Ranks·
    US
    AGEN
    -2.64%

    Promising Developments and Strategic Partnerships Justify Buy Rating for Agenus

    Emily Bodnar, an analyst from H.C. Wainwright, has maintained a Buy rating on Agenus with a price target of $23.00. This rating is supported by promising developments in Agenus's clinical trials, particularly a Phase 1b trial showing significant survival benefits in cancer patients. Additionally, a strategic partnership with Zydus is expected to provide financial support for the Phase 3 BATTMAN trial. Recent compassionate use authorization in France further enhances the company's regulatory prospects, justifying the positive outlook.

    Tip Ranks·
    US
    AGEN
    -2.64%
    Tip Ranks·
    US
    AGEN
    -2.64%

    AGENUS INC SEC 10-Q Report

    Agenus Inc. has released its latest Form 10-Q report, showing significant improvements in financial and operational performance. Total revenues increased to $79.992 million, with a notable net income of $7.529 million, a turnaround from a net loss of $(185.465) million last year. The company is advancing its lead assets in clinical programs and has received Fast Track designation from the FDA for specific cancer treatments. Future plans include launching registration-enabling trials for its products and pursuing collaborations with major pharmaceutical companies to enhance its immuno-oncology pipeline.

    TradingView·
    US
    AGEN
    -2.64%
    TradingView·
    US
    AGEN
    -2.64%
    © 2025 Longbridge｜Disclaimer